These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 22142661

  • 1. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J, Rugo HS.
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [Abstract] [Full Text] [Related]

  • 2. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
    Gnant M.
    Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R.
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates as anticancer therapy for early breast cancer.
    Mahtani R, Jahanzeb M.
    Clin Breast Cancer; 2010 Oct 01; 10(5):359-66. PubMed ID: 20920980
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New results from the use of bisphosphonates in cancer patients.
    Coleman R, Gnant M.
    Curr Opin Support Palliat Care; 2009 Sep 01; 3(3):213-8. PubMed ID: 19561507
    [Abstract] [Full Text] [Related]

  • 8. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A.
    Breast Cancer Res Treat; 2010 Aug 01; 122(3):627-36. PubMed ID: 20490653
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.
    Neville-Webbe HL, Coleman RE.
    Eur J Cancer; 2010 May 01; 46(7):1211-22. PubMed ID: 20347292
    [Abstract] [Full Text] [Related]

  • 10. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ, Kaura S.
    J Med Econ; 2012 May 01; 15(1):175-84. PubMed ID: 22017235
    [Abstract] [Full Text] [Related]

  • 11. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.
    Clin Cancer Res; 2003 Jul 01; 9(7):2394-9. PubMed ID: 12855610
    [Abstract] [Full Text] [Related]

  • 12. New role for an established drug? Bisphosphonates as potential anticancer agents.
    Koul HK, Koul S, Meacham RB.
    Prostate Cancer Prostatic Dis; 2012 Jun 01; 15(2):111-9. PubMed ID: 21876554
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates: prevention of bone metastases in breast cancer.
    Gnant M, Dubsky P, Hadji P.
    Recent Results Cancer Res; 2012 Jun 01; 192():65-91. PubMed ID: 22307370
    [Abstract] [Full Text] [Related]

  • 14. The evolving role of bone-conserving therapy in patients with breast cancer.
    Brufsky AM.
    Semin Oncol; 2010 Jun 01; 37 Suppl 1():S12-9. PubMed ID: 20682367
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT, Col N.
    Breast Dis; 2011 Jun 01; 33(2):93-101. PubMed ID: 22142660
    [Abstract] [Full Text] [Related]

  • 16. Bone-modifying agents as adjuvant therapy for early-stage breast cancer.
    Figueroa-Magalhães MC, Miller RS.
    Oncology (Williston Park); 2012 Oct 01; 26(10):955-62. PubMed ID: 23176008
    [Abstract] [Full Text] [Related]

  • 17. Moving into the future: treatment of bone metastases and beyond.
    Hortobagyi GN.
    Cancer Treat Rev; 2005 Oct 01; 31 Suppl 3():9-18. PubMed ID: 16249057
    [Abstract] [Full Text] [Related]

  • 18. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL, Gnant M, Coleman RE.
    Semin Oncol; 2010 Jun 01; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates in breast cancer: antitumor effects.
    Aft R.
    Clin Adv Hematol Oncol; 2011 Apr 01; 9(4):292-9. PubMed ID: 21558988
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R, Olson K, Van Poznak C.
    Hematol Oncol Clin North Am; 2007 Apr 01; 21(2):341-67. PubMed ID: 17512453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.